Peptide Library

Human study PLS-00177

Increases in plasma Tβ4 after intracardiac cell therapy in chronic ischemic heart failure is associated with symptomatic improvement.

Other design · Not reported participants enrolled · not included in the assessments (wrong compound)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Increases in plasma Tβ4 after intracardiac cell therapy in chronic ischemic heart failure is associated with symptomatic improvement.primary · Regenerative medicine · 2015-05-01 · PMID 26022762 · DOI

Design and participants

Design
Other design
Population
Patients with chronic ischemic heart failure enrolled in the REGENERATE-IHD cell therapy trial (13 BMSC recipients, 14 controls).
Conditions
Chronic ischemic heart failure
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported
Funding
Research Support, Non-U.S. Gov't (per publication type); funder not named

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): This exploratory study suggests Tβ4 may be relevant in human heart disease and cell therapy, and highlights the need for further study of Tβ4 in human cardiovascular disease.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Tβ4 was not administered; it was only measured as an endogenous biomarker after stem cell therapy.
    • small or imprecise: Only 13 BMSC patients and 14 controls were analysed; no effect sizes are reported.
    • abstract only: Only the abstract is available; methods, statistics and missing data cannot be assessed.
    • confounding: The association between Tβ4 change and NYHA improvement is correlational and not protected by randomization.
    • inappropriate population: Tβ4 was not given to participants; it was measured as an endogenous marker after stem cell therapy, so the study says nothing about Tβ4 as a treatment.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • arms: PMID 26022762, abstract (sentence 3) · extracted by AI (automated, not verified by a person) · abstract only
    • author_conclusion: PMID 26022762, abstract (sentence 6) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 26022762, abstract (sentence 2) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 26022762, abstract (sentences 2-6) · extracted by AI (automated, not verified by a person) · abstract only
    • outcomes: PMID 26022762, abstract (sentences 4-5) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 26022762, abstract (sentence 3) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 26022762, title (title) · extracted by AI (automated, not verified by a person) · abstract only
    • results: PMID 26022762, abstract (sentences 4-5) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).